Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Investors and analysts will be watching closely how Lilly overcomes these obstacles in the changing obesity treatment ...

To say, as CEO David Ricks did, that this was a good quarter, is an understatement. Mounjaro in diabetes brought in $3.84 ...

Be sure to follow your doctor’s instructions. Zepbound is available as a liquid solution that’s given as an injection under your skin using the injection pen or a vial and syringe. Your doctor ...

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...

This marks a shift in the agency's approach to treating the global obesity problem. Read more at straitstimes.com. Read more ...

In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...

It now offers the two lowest doses of Zepbound for $349 and $499 for a month's supply. CVS is also making those vials available in pharmacies. Weekly U.S. prescriptions of Wegovy have plateaued ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...